Skip to content

Study · Non-randomized trial · 1986

4 results

Effect of infused vasoactive intestinal peptide on airway function in normal subjects.

Palmer JB, Cuss FM, Warren JB, Blank M, Bloom SR, Barnes PJ

Thorax1 Sept 1986Cited by 27 (Europe PMC)

PMID3787552 (opens in a new tab)PMCIDPMC460426 (opens in a new tab)DOI10.1136/thx.41.9.663 (opens in a new tab)PepBankPUB-03787552
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialActivity measurement

    In normal subjects, infused VIP at 6 pmol/kg/min lowered mean systolic blood pressure from 108 to 88 mm Hg.

    In plain wordsIn healthy people, a VIP infusion lowered systolic blood pressure.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseSystolic blood pressure
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    6 pmol/kg/min · 15 minutesAs given in this study (human).

    Measurements

    Systolic blood pressure
    108 mm Hg
    before VIP
    Systolic blood pressure
    88 mm Hg
    VIP 6 pmol/kg/min

    Source sentences

    Summary
    At 6 pmol/kg/min it caused a mean fall in systolic blood pressure from 108 to 88 mm Hg and a rise in heart rate from 71 to 95 beats/min.
    2 context sentences
    Summary · context
    The effect on airway function of infused vasoactive intestinal peptide was studied in normal subjects, who readily develop bronchodilation in response to a beta agonist.
    Summary · context
    Incremental doses of 1, 3, and 6 pmol/kg/min of vasoactive intestinal peptide were infused for 15 minutes.
  2. 02HumanNon-randomized trialActivity measurement

    In normal subjects, infused VIP at 6 pmol/kg/min raised mean heart rate from 71 to 95 beats/min.

    In plain wordsIn healthy people, a VIP infusion raised heart rate.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseHeart rate
    Study

    n: not reported in source

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    6 pmol/kg/min · 15 minutesAs given in this study (human).

    Measurements

    Heart rate
    71 beats/min
    before VIP
    Heart rate
    95 beats/min
    VIP 6 pmol/kg/min

    Source sentences

    Summary
    At 6 pmol/kg/min it caused a mean fall in systolic blood pressure from 108 to 88 mm Hg and a rise in heart rate from 71 to 95 beats/min.
    2 context sentences
    Summary · context
    The effect on airway function of infused vasoactive intestinal peptide was studied in normal subjects, who readily develop bronchodilation in response to a beta agonist.
    Summary · context
    Incremental doses of 1, 3, and 6 pmol/kg/min of vasoactive intestinal peptide were infused for 15 minutes.
  3. 03HumanNon-randomized trialEfficacy outcome

    In normal subjects, infused VIP at 1, 3 and 6 pmol/kg/min caused no significant change in specific airways conductance.

    In plain wordsIn healthy people, a VIP infusion did not change airway openness.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeSpecific airways conductance (sGaw)
    Study

    n: not reported in source

    Outcome group
    Respiratory function · Respiratory
    Studied dose
    1, 3 and 6 pmol/kg/min · 15 minutesAs given in this study (human).

    Source sentences

    Summary
    There was no significant change in specific airways conductance (sGaw) at any dose of vasoactive intestinal peptide.
    2 context sentences
    Summary · context
    The effect on airway function of infused vasoactive intestinal peptide was studied in normal subjects, who readily develop bronchodilation in response to a beta agonist.
    Summary · context
    Incremental doses of 1, 3, and 6 pmol/kg/min of vasoactive intestinal peptide were infused for 15 minutes.
  4. 04HumanNon-randomized trialEfficacy outcome

    In normal subjects, infused VIP caused no significant change in the cumulative dose-response curve for inhaled isoprenaline.

    In plain wordsIn healthy people, a VIP infusion did not change the airway response to inhaled isoprenaline.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeBronchodilator response to inhaled isoprenaline
    Study

    n: not reported in source

    Outcome group
    Respiratory function · Respiratory
    Studied dose
    1, 3 and 6 pmol/kg/min · 15 minutesAs given in this study (human).

    Source sentences

    Summary
    Infused peptide caused no significant change in the cumulative dose-response curve for inhaled isoprenaline.
    2 context sentences
    Summary · context
    The effect on airway function of infused vasoactive intestinal peptide was studied in normal subjects, who readily develop bronchodilation in response to a beta agonist.
    Summary · context
    Incremental doses of 1, 3, and 6 pmol/kg/min of vasoactive intestinal peptide were infused for 15 minutes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.